Cardiology Coding Alert

Reader Question :

Leave G9143 to Testing Entity

Question: When should I use the new testing code for warfarin (G9143)?Wisconsin SubscriberAnswer: You should report G9143 (Warfarin responsiveness testing by genetic technique using any method, any number of specimen[s]) only if you're reporting the actual testing to see how a patient's genetic makeup affects the body's response to warfarin, also called pharmacogenomic testing. So a lab is likely to report this code.Background: As of Aug. 3, 2009, Medicare covers pharmacogenomic testing to predict warfarin responsiveness only "in the context of a prospective randomized, controlled clinical study when that study meets certain criteria as outlined in the Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Section 90.1," states MLN Matters article MM6715 (www.cms.hhs.gov/MLNMattersArticles/downloads/MM6715.pdf).According to the article, testing is covered if the beneficiary meets three conditions:1. Is a candidate for anticoagulation therapy with warfarin2. Has not been previously tested for CYP2C9 or VKORC1 alleles (the alleles warfarin responsiveness is limited [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Cardiology Coding Alert

View All